AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 76 filers reported holding AERIE PHARMACEUTICALS INC in Q3 2014. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $255,016,000 | +224.0% | 16,855 | +60.6% | 0.00% | – |
| Q2 2022 | $78,698,000 | -28.7% | 10,493 | -13.4% | 0.00% | – |
| Q1 2022 | $110,319,000 | +74.8% | 12,123 | +34.8% | 0.00% | – |
| Q4 2021 | $63,124,000 | -27.1% | 8,992 | +18.5% | 0.00% | – |
| Q3 2021 | $86,537,000 | +225.8% | 7,591 | +357.6% | 0.00% | – |
| Q2 2021 | $26,561,000 | -69.5% | 1,659 | -65.9% | 0.00% | – |
| Q1 2021 | $87,027,000 | -9.0% | 4,870 | -31.2% | 0.00% | – |
| Q4 2020 | $95,597,000 | -5.6% | 7,076 | -17.7% | 0.00% | – |
| Q3 2020 | $101,234,000 | +187.0% | 8,601 | +259.9% | 0.00% | – |
| Q2 2020 | $35,276,000 | -81.5% | 2,390 | -83.1% | 0.00% | – |
| Q1 2020 | $191,079,000 | +31.1% | 14,154 | +134.7% | 0.00% | – |
| Q4 2019 | $145,745,000 | -0.4% | 6,030 | -20.8% | 0.00% | – |
| Q3 2019 | $146,264,000 | -0.7% | 7,610 | +52.7% | 0.00% | – |
| Q2 2019 | $147,277,000 | -63.4% | 4,984 | -41.2% | 0.00% | -100.0% |
| Q1 2019 | $402,895,000 | +968.0% | 8,482 | +711.7% | 0.00% | – |
| Q4 2018 | $37,724,000 | -72.8% | 1,045 | -53.7% | 0.00% | – |
| Q3 2018 | $138,857,000 | +4.4% | 2,256 | +14.6% | 0.00% | – |
| Q2 2018 | $133,006,000 | -66.8% | 1,969 | -73.3% | 0.00% | -100.0% |
| Q1 2018 | $400,311,000 | -3.3% | 7,379 | +6.5% | 0.00% | 0.0% |
| Q4 2017 | $413,828,000 | +129.8% | 6,926 | +86.9% | 0.00% | – |
| Q3 2017 | $180,112,000 | -7.6% | 3,706 | -0.1% | 0.00% | -100.0% |
| Q2 2017 | $195,013,000 | +3157.8% | 3,711 | +2711.4% | 0.00% | – |
| Q1 2017 | $5,986,000 | -65.8% | 132 | -71.5% | 0.00% | – |
| Q4 2016 | $17,525,000 | -72.0% | 463 | -72.1% | 0.00% | – |
| Q3 2016 | $62,648,000 | +279.9% | 1,660 | +77.2% | 0.00% | – |
| Q2 2016 | $16,491,000 | -83.2% | 937 | -76.8% | 0.00% | – |
| Q4 2015 | $98,180,000 | +22.0% | 4,032 | -11.2% | 0.00% | – |
| Q3 2015 | $80,504,000 | +167.2% | 4,538 | +165.8% | 0.00% | – |
| Q2 2015 | $30,129,000 | +289.2% | 1,707 | +591.1% | 0.00% | – |
| Q1 2015 | $7,741,000 | -50.9% | 247 | -67.6% | 0.00% | – |
| Q3 2014 | $15,766,000 | +327.1% | 762 | +411.4% | 0.00% | – |
| Q2 2014 | $3,691,000 | +1709.3% | 149 | +1046.2% | 0.00% | – |
| Q1 2014 | $204,000 | -88.0% | 13 | -86.3% | 0.00% | – |
| Q4 2013 | $1,706,000 | – | 95 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
| LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
| DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
| DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
| Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
| PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
| Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |